Cargando…

Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews

BACKGROUND: Although cannabis and cannabinoids are widely used with therapeutic purposes, their claimed efficacy is highly controversial. For this reason, medical cannabis use is a broad field of research that is rapidly expanding. Our objectives are to identify, characterize, appraise, and organize...

Descripción completa

Detalles Bibliográficos
Autores principales: Montero-Oleas, Nadia, Arevalo-Rodriguez, Ingrid, Nuñez-González, Solange, Viteri-García, Andrés, Simancas-Racines, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076827/
https://www.ncbi.nlm.nih.gov/pubmed/32020875
http://dx.doi.org/10.1186/s12906-019-2803-2
_version_ 1783507294761254912
author Montero-Oleas, Nadia
Arevalo-Rodriguez, Ingrid
Nuñez-González, Solange
Viteri-García, Andrés
Simancas-Racines, Daniel
author_facet Montero-Oleas, Nadia
Arevalo-Rodriguez, Ingrid
Nuñez-González, Solange
Viteri-García, Andrés
Simancas-Racines, Daniel
author_sort Montero-Oleas, Nadia
collection PubMed
description BACKGROUND: Although cannabis and cannabinoids are widely used with therapeutic purposes, their claimed efficacy is highly controversial. For this reason, medical cannabis use is a broad field of research that is rapidly expanding. Our objectives are to identify, characterize, appraise, and organize the current available evidence surrounding therapeutic use of cannabis and cannabinoids, using evidence maps. METHODS: We searched PubMed, EMBASE, The Cochrane Library and CINAHL, to identify systematic reviews (SRs) published from their inception up to December 2017. Two authors assessed eligibility and extracted data independently. We assessed methodological quality of the included SRs using the AMSTAR tool. To illustrate the extent of use of medical cannabis, we organized the results according to identified PICO questions using bubble plots corresponding to different clinical scenarios. RESULTS: A total of 44 SRs published between 2001 and 2017 were included in this evidence mapping with data from 158 individual studies. We extracted 96 PICO questions in the following medical conditions: multiple sclerosis, movement disorders (e.g. Tourette Syndrome, Parkinson Disease), psychiatry conditions, Alzheimer disease, epilepsy, acute and chronic pain, cancer, neuropathic pain, symptoms related to cancer (e.g. emesis and anorexia related with chemotherapy), rheumatic disorders, HIV-related symptoms, glaucoma, and COPD. The evidence about these conditions is heterogeneous regarding the conclusions and the quality of the individual primary studies. The quality of the SRs was moderate to high according to AMSTAR scores. CONCLUSIONS: Evidence on medical uses of cannabis is broad. However, due to methodological limitations, conclusions were weak in most of the assessed comparisons. Evidence mapping methodology is useful to perform an overview of available research, since it is possible to systematically describe the extent and distribution of evidence, and to organize scattered data.
format Online
Article
Text
id pubmed-7076827
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70768272020-03-19 Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews Montero-Oleas, Nadia Arevalo-Rodriguez, Ingrid Nuñez-González, Solange Viteri-García, Andrés Simancas-Racines, Daniel BMC Complement Med Ther Research Article BACKGROUND: Although cannabis and cannabinoids are widely used with therapeutic purposes, their claimed efficacy is highly controversial. For this reason, medical cannabis use is a broad field of research that is rapidly expanding. Our objectives are to identify, characterize, appraise, and organize the current available evidence surrounding therapeutic use of cannabis and cannabinoids, using evidence maps. METHODS: We searched PubMed, EMBASE, The Cochrane Library and CINAHL, to identify systematic reviews (SRs) published from their inception up to December 2017. Two authors assessed eligibility and extracted data independently. We assessed methodological quality of the included SRs using the AMSTAR tool. To illustrate the extent of use of medical cannabis, we organized the results according to identified PICO questions using bubble plots corresponding to different clinical scenarios. RESULTS: A total of 44 SRs published between 2001 and 2017 were included in this evidence mapping with data from 158 individual studies. We extracted 96 PICO questions in the following medical conditions: multiple sclerosis, movement disorders (e.g. Tourette Syndrome, Parkinson Disease), psychiatry conditions, Alzheimer disease, epilepsy, acute and chronic pain, cancer, neuropathic pain, symptoms related to cancer (e.g. emesis and anorexia related with chemotherapy), rheumatic disorders, HIV-related symptoms, glaucoma, and COPD. The evidence about these conditions is heterogeneous regarding the conclusions and the quality of the individual primary studies. The quality of the SRs was moderate to high according to AMSTAR scores. CONCLUSIONS: Evidence on medical uses of cannabis is broad. However, due to methodological limitations, conclusions were weak in most of the assessed comparisons. Evidence mapping methodology is useful to perform an overview of available research, since it is possible to systematically describe the extent and distribution of evidence, and to organize scattered data. BioMed Central 2020-01-15 /pmc/articles/PMC7076827/ /pubmed/32020875 http://dx.doi.org/10.1186/s12906-019-2803-2 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Montero-Oleas, Nadia
Arevalo-Rodriguez, Ingrid
Nuñez-González, Solange
Viteri-García, Andrés
Simancas-Racines, Daniel
Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews
title Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews
title_full Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews
title_fullStr Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews
title_full_unstemmed Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews
title_short Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews
title_sort therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076827/
https://www.ncbi.nlm.nih.gov/pubmed/32020875
http://dx.doi.org/10.1186/s12906-019-2803-2
work_keys_str_mv AT monterooleasnadia therapeuticuseofcannabisandcannabinoidsanevidencemappingandappraisalofsystematicreviews
AT arevalorodriguezingrid therapeuticuseofcannabisandcannabinoidsanevidencemappingandappraisalofsystematicreviews
AT nunezgonzalezsolange therapeuticuseofcannabisandcannabinoidsanevidencemappingandappraisalofsystematicreviews
AT viterigarciaandres therapeuticuseofcannabisandcannabinoidsanevidencemappingandappraisalofsystematicreviews
AT simancasracinesdaniel therapeuticuseofcannabisandcannabinoidsanevidencemappingandappraisalofsystematicreviews